Press Releases

Teva Pharmaceutical Industries Ltd. and Bioeq AG today announced that they have entered into a strategic partnership for the exclusive commercialization of Bioeq's FYB201, a biosimilar candidate to Lucentis® (ranibizumab) in Europe, Canada, Israel and New Zealand. This strategic partnership combines Teva’s long-standing commercial presence, extensive distribution network and wide-reaching sales and marketing activities across Europe and international markets with Bioeq

Ahead of Pharmapack Europe 2021 (Paris Expo, Porte de Versailles, 13-14 October) – the returning European event dedicated to drug packaging and delivery – there has been a huge swathe of innovation across the industry, with more than 53 FDA approvals in 2020 and 26 approvals in 2021. In fact, since February 2020 when the event was held last, the Pharmapack Innovation Index – a reputation score carried out amongst the industry ranking the most innovative drug delive

Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimer’s through a simple saliva or blood sample. The product is anticipated to be available to physicians in the coming months. Physicians can use the genoSCORE test to assess patients before symptoms arise, and prior to invasive cerebrospinal fluid (CSF) testing or expensive scanning techniques. Furthermore

Valent BioSciences and Valent U.S.A. are collaborating with Halo to launch an open innovation initiative utilizing Halo’s state-of-the-art technology platform. This platform connects enterprises with universities, researchers and start-ups around the world to effectively crowd-source innovative ideas, technologies and solutions with experts who are working on either solving the same problems or similar problems across a range of scientific endeavors that could be applied elsewhere.

AbCellera announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera’s capabilities in bringing new antibody therapies to clinical trials, supporting Canada’s efforts to respond quickly and effectively to future pandemics and providing AbCellera’s partners with

Nu-Tek BioSciences, an innovative manufacturer of industrial ingredients used in the development and manufacturing of pharmaceuticals, broke ground today on its 60,000 square-foot manufacturing facility in Austin, Minnesota. The building will be home to the first dedicated animal-free peptone manufacturing facility in the U.S. and a long-term solution for raw materials needed for certain biologics manufacturing. Located in the Creekside Business Park, the Nu-Tek project will sit on

Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the publication of the results from two Phase 2 clinical studies investigating tildacerfont in adult patients with classic CAH in the Journal of Clinical Endocrinology and Metabolism. “The data published in the Journal of Clinical Endocrinology and Metabolism demonstrates the

Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a response to the COVID-19 pandemic, by joining the speaker faculty at Reuters Events Pharma Europe 2021. Reuters Events will bring together another 150 life sciences leaders as speakers, and thousands more executive attendees, to showcase the investments being made as the industry accelerates its digital transformation platform to ensure c

Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, today announced the expansion of its ATMP development facilities under biosafety level S2 (BSL2 / S2). Re-construction of an existing building near the Coriolis headquarters has started in March this year and the laboratories are planned to be operational in Q4 2021. The new facilities will increase Coriolis’ total floor spac

Reven Holdings, Inc. is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for sepsis, cancer, viral illnesses, including COVID-19 - and inflammatory disorders. Reven today announced the publication of a peer-reviewed article in the prestigious medical journal, Biomedicine and Pharmacotherapy. In this new publication, Reven Pharmaceuticals team reports positive results regarding the safety